Water-in-oil microemulsions for oilfield applications

Information

  • Patent Grant
  • 9222013
  • Patent Number
    9,222,013
  • Date Filed
    Friday, November 13, 2009
    15 years ago
  • Date Issued
    Tuesday, December 29, 2015
    8 years ago
Abstract
A well treatment microemulsion includes an oil external phase, an internal aqueous phase and a hydrophilic surfactant. The surfactant has a hydrophile lipophile balance of between 8-18. The oil external phase may include d-Limonene, xylenes, light mineral oil, or kerosene. The surfactant is configured to emulsify the water of the internal aqueous phase into the oil of the external (continuous) phase. The surfactant may include polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan tristearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate or mixtures therebetween. The use of hydrophilic surfactants to emulsify an internal aqueous phase within an oil external microemulsion produces unexpected and beneficial results.
Description
FIELD OF THE INVENTION

The present invention generally relates to the production of petroleum and more particularly to compositions and processes for improving the recovery of petroleum from a subterranean geological formation.


BACKGROUND OF THE INVENTION

For many years, petroleum has been recovered from subterranean reservoirs through the use of drilled wells and production equipment. During the production of desirable hydrocarbons, such as crude oil and natural gas, a number of other naturally occurring substances may also be encountered within the subterranean environment.


Many undesirable downhole products must be managed during the production of hydrocarbons. For example, scale, paraffins, fines, sulfur, heavy oil tar by-products, hydrogen sulfide, and water blocks commonly accumulate in and around the formation, well casing, production tubing and recovery equipment. Alternatively, it may be necessary to remove injected fluids from the near wellbore area, such as drilling fluids, cement filtrate, kill fluids, polymers and water blocks. To maintain an efficient recovery of petroleum, it is frequently necessary to clean or remove these accumulations and deposits.


The removal of unwanted deposits from the wellbore and production equipment is generally referred to as “remediation.” In contrast, the term “stimulation” generally refers to the treatment of geological formations to improve the recovery of hydrocarbons. Common stimulation techniques include well fracturing and acidizing operations. Well remediation and stimulation are important services that are offered through a variety of techniques by a large number of companies.


The effectiveness of well remediation and stimulation operations is greatly affected by the chemical agents used during these services. Operators have discovered that microemulsions can offer an advantageous vehicle for delivering solvents or other treatment chemicals to a targeted treatment area. Microemulsions are characterized as either water-in-oil (an aqueous phase is dispersed in an oil phase) or oil-in-water (an oil phase dispersed in an aqueous phase) mixtures. Microemulsions comprise droplets having a diameter in the range of about 1-100 nm. These systems appear clear or transparent to the human eye compared to conventional emulsion systems which have droplet sizes >400 nm in diameter and a cloudy appearance. Microemulsions are thermodynamically stable and exhibit no phase separation.


The separation of the oil and water phases depends on the creation of an interface of surfactant molecules between the water and oil molecules. Nonionic surfactants are often classified according to the hydrophile-lipophile balance (HLB) system. The HLB value of a surfactant is a measure of the degree to which it is hydrophilic or lipophilic, determined by calculating values for the different regions of the molecule. Originally, the HLB value was defined as a relative measure of the ratio of the weight percent ethylene oxide (EO) in a given nonionic surfactant.


Surfactants with lower HLB values are typically used for making oil-external (water-in-oil) microemulsions, while surfactants with higher HLB values are used for making water external (oil-in-water) microemulsions.


The prior art includes many examples that show that surfactants with an HLB generally greater than about 8 will produce oil-in-water emulsions, while surfactants with an HLB of about 3 to 8 will produce water-in-oil emulsions.


U.S. Pat. No. 7,380,606 (Pursley, et al.; Jun. 3, 2008) titled “Composition and Process for Well Cleaning” states that water-in-oil microemulsions should be prepared using surfactants with an HLB value of between 3 and 8, while oil-in-water microemulsions are prepared with surfactants having an HLB of 8 to 18.


An article by D. F. Brost and J. Silveira titled, “Surfactants Assist Water-in-Oil Monitoring by Fluorescence” in the October 2008 online issue of World Oil states, “Surfactants with an HLB less than 10 stabilize water-in-oil emulsions. Surfactants with an HLB greater than 10 stabilize oil-in-water emulsions. Within that group, surfactants with an HLB of 12-15 act as detergents and are commonly used to remove oil from solid surfaces.”


U.S. Pat. No. 3,919,411 titled, “Injectible Adjuvant and Compositions Including Such Adjuvant”, Nov. 11, 1975 by Glass, et al. states, “Where surfactants are used for dispersing oil in water, the final HLB number should be above 6. In the case where surfactants are used of the type for dispersing water in oil, the final HLB number should be below 6.”


In a presentation given to the Midwest Chapter of the Society of Cosmetic Chemists in 2004, Uniqema reported that for making water-in-oil emulsions, surfactants with HLBs of 4-6 should be chosen, while surfactants with HLBs of 8-16 should be used when making oil-in-water emulsions.


In direct contrast to the prior art, the present invention describes the surprising discovery that high HLB surfactants can be used to produce water-in-oil microemulsions that find use in oilfield and well treatment applications.


Although a number of compounds and techniques are known in the prior art, there is a continued need for more effective microemulsions for remediation stimulation services. There is a particular need to identify new surfactants and surfactant mixtures that can be used to prepare stable microemulsions.


SUMMARY OF THE INVENTION

In preferred embodiments, a well treatment microemulsion includes an oil external phase, an internal aqueous phase and a surfactant. The surfactant has a hydrophile lipophile balance of between 8-18. The oil external phase may include but is not necessarily limited to d-Limonene, xylenes, light mineral oil, or kerosene. The surfactant is configured to emulsify the water of the internal aqueous phase into the oil of the external (continuous) phase. Suitable surfactants may include but are not necessarily limited to polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan tristearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate or mixtures therebetween.







DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In preferred embodiments, the present invention relates to the preparation of an oil external microemulsion, using a high HLB surfactant or surfactant mixture. It is well known that when two or more surfactants are mixed together, the HLB of the resulting combination is a weighted average of the HLBs of each of the components of the surfactant mixture. This HLB is reported simply as the average HLB. Select surfactants and surfactant mixtures with high HLB values have been discovered to emulsify water in a hydrocarbon oil phase. The use of a high HLB surfactant or surfactant mixture provides a new range of surfactants that have not previously been used in oil external microemulsions. In a presently preferred embodiment, the well treatment microemulsion includes an oil external (continuous) phase, an aqueous internal (dispersed) phase, and a surfactant component. The water-in-oil microemulsion may also include an alcohol component. The aqueous phase is preferably formed with water.


The oil external phase preferably consists of a hydrocarbon terpene or mixture of hydrocarbon terpenes. In preferred embodiments, the oil external phase is formed by using terpene hydrocarbons derived from citrus, pine, eucalyptus, peppermint or other sources. In a particularly preferred embodiment, the oil external phase is prepared using d-Limonene (CAS #94266-47-4; citrus terpenes). d-Limonene is commercially available from a variety of sources and is characterized as a biodegradable solvent. In alternate preferred embodiments, the oil external phase is prepared from a mixture of terpene hydrocarbons. In yet another preferred embodiment, the oil external phase is prepared from non-terpene hydrocarbons, such as xylenes, paraffin oil, a mixture of cycloparaffinic and isoparaffinic hydrocarbon, and mineral oil.


In a preferred embodiment, the surfactant component is selected as a nonionic surfactant or surfactant mixture having an HLB value of between 8 and 18. In a more particularly preferred embodiment, the selected surfactant or surfactant mixture has an HLB value of between 10 and 17.


In a particularly preferred embodiment, the surfactant component is an ethoxylated alcohol. In a more preferred embodiment, the surfactant component is an ethoxylated C8-C18 alcohol. In a still more preferred embodiment, the surfactant component is an ethoxylated C8-C18 alcohol with 5-20 moles of ethylene oxide (EO).


In a particularly preferred embodiment, the surfactant component is an ethoxylated vegetable oil. In a more preferred embodiment, the surfactant component is an ethoxylated castor oil. In a still more preferred embodiment, the surfactant component is an ethoxylated castor oil with 25-45 moles of EO.


In a particularly preferred embodiment, the surfactant component is an ethoxylated amide. In a more preferred embodiment, the surfactant component is an ethoxylated C8-C18 amide. In a still more preferred embodiment, the surfactant component is an ethoxylated C8-C18 amide with 5-20 moles of EO.


In another particularly preferred embodiment, the surfactant component is an ethoxylated fatty acid. In a more preferred embodiment, the surfactant component is an ethoxylated C8-C18 fatty acid. In a still more preferred embodiment, the surfactant component is an ethoxylated C8-C18 fatty acid with 5-20 moles of EO.


In another preferred embodiment, the surfactant component is a polyoxyethylene fatty glyceride or a polyoxyethylene hydrogenated castor oil (ethoxylated castor oil).


In another preferred embodiment, the surfactant component is a polyoxyethylene sorbitan ester. In a more preferred embodiment, the surfactant component is a polyoxyethylene sorbitan monoester. In a still more preferred embodiment, the surfactant component is a polyoxyethylene sorbitan monooleate.


In another particularly preferred embodiment, the surfactant component is a combination of two or more of the following: ethoxylated alcohol, ethoxylated vegetable oil, ethoxylated amide, ethoxylated fatty acid, polyoxyethylene fatty glyceride, and polyoxyethylene sorbitan ester. In a more preferred embodiment, the surfactant component is a combination of two or more of the following: ethoxylated C8-C18 alcohol, ethoxylated castor oil, ethoxylated C8-C18 amide, ethoxylated C8-C18 fatty acid, polyoxyethylene fatty glyceride, and polyoxyethylene sorbitan monoester. In a still more preferred embodiment, the surfactant component is a combination of two or more of the following: ethoxylated C8-C18 alcohol with 5-20 moles of EO, ethoxylated castor oil with 25-45 moles of EO, ethoxylated C8-C18 amide with 5-20 moles of EO, ethoxylated C8-C18 fatty acid with 5-20 moles of EO, polyoxyethylene fatty glyceride, and polyoxyethylene sorbitan monooleate. In alternate preferred embodiments, other nonionic surfactants can be included with these combinations, as long as the HLB of the surfactant mixture is between 8 and 18. For example, sorbitan monooleate (HLB 4.3) can be included with one or more nonionic surfactants to create a suitable surfactant combination having an HLB between 8 and at least 11.


Some examples of surfactants that have been successfully used to create oil-external microemulsions include Stepantex CO-30 (ethoxylated castor oil with 30 moles of EO, sold by Stepan Company), Tomadol 91-6 (ethoxylated C9-C11 alcohol with 6 moles of EO, sold by Air Products), Biosoft N91-6 (ethoxylated C9-C11 alcohol with 6 moles of EO, sold by Stepan Company), Tween 20 (polyoxyethylene sorbitan monolaurate, sold by Croda USA), Tween 40 (polyoxyethylene sorbitan monopalmitate, sold by Croda USA), Tween 60 (polyoxyethylene sorbitan monostearate, sold by Croda USA), Tween (polyoxyethylene sorbitan tristearate, sold by Croda USA), Tween 80 (polyoxyethylene sorbitan monooleate, sold by Croda USA), Tween 81 (polyoxyethylene sorbitan monooleate, sold by Croda USA), a combination of Span 80 (sorbitan monooleate) and Cirrasol G-1292 Special (polyoxyethylene fatty glyceride; both sold by Croda USA), and Biosoft N1-9 (ethoxylated C11 alcohol with 9 moles of EO, sold by Stepan Company). It should be noted that surfactants and mixtures of surfactants (also known as “surfactant packages”) often contain ingredients in addition to the specified surface active agents. These ingredients can vary from supplier to supplier, and may even vary within a particular supplier, as long as the resulting surfactant or surfactant package meets certain performance requirements and/or physical specifications. These ingredients may include normal product variations due to the manufacturing processes of the surfactant or surfactant package, and they may also include materials that are naturally introduced by the source feedstock. Other ingredients may be intentionally added to the surfactant or surfactant package. These ingredients include, but are not limited to, stabilizers, modifiers, solvents, antioxidants, dispersants, solubilizers, handling aids, physical property modifiers, and the like.


In yet another alternate preferred embodiment, the surfactant component selected is an anionic surfactant, including but not limited to sulfonates, specifically internal olefin sulfonates and linear alkylbenzene sulfonates. Presently preferred anionic surfactants include C15-C18 internal olefin sulfonates (available as Petrostep S2, sold by Stepan Company) and linear alkylbenzene sulfonate/linear sodium dodecylbenzene sulfonates (available as Polystep LAS-50, sold by Stepan Company).


In yet another alternate preferred embodiment, the surfactant component is selected as a combination of nonionic and anionic surfactants, such as but not limited to ethoxylated alcohols, ethoxylated castor oil, and sulfonates. Presently preferred nonionic/anionic surfactant combinations comprise ethoxylated C8-C18 alcohol with 5-20 moles EO, ethoxylated castor oil with 25-45 moles of EO, and C15-C18 internal olefin sulfonates.


The alcohol molecules of the well treatment microemulsion stabilize the microemulsion through interactions at the water and oil interface, thereby further stabilizing the microemulsion. The alcohol also lowers the freezing point of the well treatment microemulsion. Although isopropanol is presently preferred, alternative suitable alcohols include midrange primary, secondary and tertiary alcohols with between 1 and 20 carbon atoms, such as ethanol, t-butanol, n-butanol, n-pentanol, n-hexanol and 2-ethyl-hexanol. Other freeze prevention additives can additionally or alternatively be added, such as detergent range alcohols ethoxylate, ethylene glycols (EG), polyethylene glycols (PEG), propylene glycols (PG) and triethylene glycols (TEG), with triethylene glycol being presently preferred.


In preferred embodiments, the well treatment microemulsion comprises 30-60% by weight terpene mixture or non-terpene hydrocarbons (oil phase), 25-50% by weight surfactant or surfactant mixture (surfactant component), 5-30% by weight water (aqueous phase), 0-3% by weight TEG (alcohol) and 0-35% isopropyl alcohol (alcohol). Using the various components identified above, the following preferred well treatment microemulsion formulations can be prepared.


Example 1

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant mixture. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 9.64% by weight isopropanol (alcohol), about 1.36% by weight triethylene glycol (alcohol), and about 32.8% by weight surfactant mixture having an average HLB of about 10 and comprising the following surfactants: (i) polyoxyethylene castor oil (Cirrasol G-1292 Special, sold by Croda USA) and (ii) sorbitan monooleate (Span 80, sold by Croda USA).


Example 2

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 35.8% by weight d-Limonene (external oil phase), about 9.4% by weight water (dispersed aqueous phase), about 32.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 20.8% by weight surfactant having an HLB of about 10 and comprising the following surfactant: polyoxyethylene sorbitan monooleate (Tween 81, sold by Croda USA).


Example 3

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant mixture. The well treatment microemulsion contains about 41.8% by weight xylenes (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 9.64% by weight isopropanol (alcohol), 1.36% by weight triethylene glycol (alcohol), and about 32.8% by weight surfactant mixture having an average HLB of about 10 and comprising the following surfactants: (i) polyoxyethylene fatty glyceride (Cirrasol G-1292 Special, sold by Croda USA) and (ii) sorbitan monooleate (Span 80, sold by Croda USA).


Example 4

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohol and a surfactant mixture. The well treatment microemulsion contains about 43% by weight of light mineral oil (external oil phase), about 10% by weight water (dispersed aqueous phase), about 11% by weight isopropanol (alcohol), and about 36% by weight of a surfactant mixture having an average HLB of about 10 and comprising the following surfactants: sorbitan monooleate (Span 80, sold by Croda USA) and polyoxyethylene sorbitan monooleate (Tween 80, sold by Croda USA).


Example 5

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 35.8% by weight d-Limonene (external oil phase), about 9.4% by weight water (dispersed aqueous phase), about 32.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 20.8% by weight surfactant having an HLB of about 10.5 and comprising the following surfactant: polyoxyethylene sorbitan tristearate (Tween 65, sold by Croda USA).


Example 6

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 9.64% by weight isopropanol (alcohol), about 1.36% by weight triethylene glycol (alcohol), and about 32.8% by weight surfactant having an HLB of about 10.8 and comprising the following surfactant: polyoxyethylene fatty glyceride (Cirrasol G-1292 Special, sold by Croda USA).


Example 7

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant package. The well treatment microemulsion contains about 41.8% by weight terpene hydrocarbon mixture-1 (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 1.6% by weight triethylene glycol (alcohol), about 6.4% by weight isopropanol (alcohol), and about 35.8% by weight surfactant mixture having an HLB of about 12.5 and comprising the following surfactant: ethoxylated C9-C11 alcohol with 6 moles EO (Tomadol 91-6, sold by Air Products).


Example 8

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant package. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 1.6% by weight triethylene glycol (alcohol), about 6.4% by weight isopropanol (alcohol), and about 35.8% by weight surfactant mixture having an average HLB of about 12.8 and comprising the following surfactants: (i) ethoxylated castor oil with 25-45 moles of EO and (ii) ethoxylated C8-C18 alcohol with 5-20 moles EO.


Example 9

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant package. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 1.6% by weight triethylene glycol (alcohol), about 6.4% by weight isopropanol (alcohol), and about 35.8% by weight surfactant having an HLB of about 13 and comprising the following surfactant: ethoxylated castor oil with 30 moles of EO (Stepantex CO 30, sold by Stepan Company).


Example 10

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant mixture. The well treatment microemulsion contains about 41.8% by weight d-Limonene (oil phase), about 14.4% by weight water (aqueous phase), about 1.6% by weight triethylene glycol (alcohol), about 6.4% by weight isopropanol (alcohol), and about 35.8% by weight surfactant mixture having an average HLB of about 13.1 and comprising the following surfactants: (i) ethoxylated C8-C18 amide with 5-20 moles of EO; (ii) ethoxylated castor oil with 25-45 moles of EO; and (iii) ethoxylated C8-C18 fatty acid with 5-20 moles of EO. Tables 1 and 2 below provides the thermal analysis and solubility tests, respectively, of the well treatment microemulsion of Example 10.









TABLE 1







Thermal Analysis of Oil External Microemulsion












Temperature
Time
Observation
Stability







 72 F.
≧24 hr
Clear
Homogenous/1 phase



120 F.
≧24 hr
Clear
Homogenous/1 phase

















TABLE 2







Solubility Tests of Oil External Microemulsion












Condensate
Isopar L
d-Limonene
Water







Soluble
Soluble
Soluble
Insoluble










Example 11

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant mixture. The well treatment microemulsion contains about 44.7% by weight citrus pine terpene-hydrocarbon mixture-1 (external oil phase), about 15.4% by weight water (dispersed aqueous phase), about 1.7% by weight triethylene glycol (alcohol), and about 38.2% by weight surfactant mixture having an average HLB of about 13.1 and comprising the following surfactants: (i) ethoxylated C8-C18 amide with 5-20 moles of EO; (ii) ethoxylated castor oil with 25-45 moles of EO; and (iii) ethoxylated C8-C18 fatty acid with 5-20 moles of EO.


Example 12

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant mixture. The well treatment microemulsion contains about 44.7% by weight citrus pine terpene-hydrocarbon mixture-2 (external oil phase), about 15.4% by weight water (dispersed aqueous phase), about 1.7% by weight triethylene glycol (alcohol), and about 38.2% by weight surfactant mixture having an average HLB of about 13.1 and comprising the following surfactants: (i) ethoxylated C8-C18 amide with 5-20 moles of EO; (ii) ethoxylated castor oil with 25-45 moles of EO; and (iii) ethoxylated C8-C18 fatty acid with 5-20 moles of EO.


Example 13

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 6.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 35.8% by weight surfactant having an HLB of about 13.9 comprising the following surfactant: ethoxylated C11 alcohol with 9 moles EO (Biosoft N1-9, sold by Stepan Company).


Example 14

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 6.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 35.8% by weight surfactant having an HLB of about 14.9 and comprising the following surfactant: polyoxyethylene sorbitan monostearate (Tween 60, sold by Croda USA).


Example 15

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohol and a surfactant. The well treatment microemulsion contains about 40.2% by weight of a mixture of Conosol 145 (external oil phase comprised of cycloparaffinic and isoparaffinic hydrocarbons, sold by Calumet Specialty Products Partners), about 13.8% by weight water (dispersed aqueous phase), about 6.2% by weight isopropanol (alcohol), and about 39.8% by weight surfactant having an HLB of about 14.9 and comprising the surfactant: polyoxyethylene sorbitan monostearate (Tween 60, sold by Croda US).


Example 16

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 9.64% by weight isopropanol (alcohol), about 1.36% by weight triethylene glycol (alcohol), and about 32.8% by weight surfactant having an HLB of about 15 and comprising the following surfactant: polyoxyethylene sorbitan monooleate (Tween 80, sold by Croda USA).


Example 17

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohol and a surfactant. The well treatment microemulsion contains about 42.5% by weight of kerosene (external oil phase), about 10.6% by weight water (dispersed aqueous phase), about 6.5% by weight tertiary butanol (alcohol), and about 40.4% by weight of a surfactant with an HLB of about 15 and comprising the following surfactant: polyoxyethylene sorbitan monooleate (Tween 80, sold by Croda USA).


Example 18

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion can be made with aromatic comprising hydrocarbons. An example includes about 41.8% by weight xylenes (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 9.64% by weight isopropanol (alcohol), 1.36% by weight triethylene glycol (alcohol), and about 32.8% by weight surfactant having an HLB of about 15 and comprising the following surfactant: polyoxyethylene sorbitan monooleate (Tween 80, sold by Croda USA).


Example 19

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 6.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 35.8% by weight surfactant having an HLB of about 15.6 and comprising the following surfactant: polyoxyethylene sorbitan monopalmitate (Tween 40, sold by Croda USA).


Example 20

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 6.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 35.8% by weight surfactant having an HLB of about 16.7 and comprising the following surfactant: polyoxyethylene sorbitan monolaurate (Tween 20, sold by Croda USA).


Example 21

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 44.7% by weight d-Limonene (external oil phase), about 15.4% by weight water (dispersed aqueous phase), about 1.7% by weight triethylene glycol (alcohol), and about 38.2% by weight anionic surfactant comprising a linear sodium dodecylbenzene sulfonate (Polystep LAS-50, sold by Stepan Company).


Example 22

An oil-external well treatment microemulsion includes a continuous oil phase, a dispersed water phase, alcohols and a surfactant. The well treatment microemulsion contains about 41.8% by weight d-Limonene (external oil phase), about 14.4% by weight water (dispersed aqueous phase), about 6.4% by weight isopropanol (alcohol), about 1.6% by weight triethylene glycol (alcohol), and about 35.8% by weight of a surfactant mixture comprising: (i) ethoxylated castor oil with 25-45 moles of EO, (ii) ethoxylated C8-C18 alcohol with 5-20 moles EO (iii), and an anionic surfactant comprising a C15-C18 internal olefin sulfonate (Petrostep S2, sold by Stepan Company).


Although for the purposes of the present disclosure preferred embodiments of the well treatment microemulsions are described in connection with well remediation, stimulation, acidizing operations, drilling operations and hydrogen sulfide mitigation applications, it will be understood that the inventive well treatment microemulsions can be used in additional, alternative applications. For example, it is contemplated that the well treatment microemulsion could also be used to clean surface equipment and downhole equipment.


In well remediation applications, the selected well treatment microemulsion is preferably injected directly into the wellbore through the production tubing or through the use of coiled tubing or similar delivery mechanisms. Once downhole, the well treatment microemulsion remedies drilling damage, fracturing fluid damage, water blocks and removes fines, asphaltenes and paraffins from the formation and wellbore. The well treatment microemulsion also serves to thin heavy hydrocarbons, alleviate water blocks and lower pore pressure in the formation.


During drilling operations, the well treatment microemulsions can be added to drilling fluids and injected into the wellbore through the drill string. The well treatment microemulsion is effective at removing fines and debris from the wellbore created by the drilling process.


The inventive well treatment microemulsions can also be used in stimulation operations.


The well treatment microemulsions can also be used to deliver acids during acidizing operations. Acids commonly used include hydrochloric, acetic, formic, and hydrochloric-hydrofluoric acids. In a presently preferred embodiment, the selected microemulsion is combined with an acidified carrier fluid to prepare a microemulsion suitable for acidizing operations.


As mentioned above, the inventive microemulsions can also be used for hydrogen sulfide mitigation. In preferred embodiments, the well treatment microemulsions are injected into the wellbore so that escaping hydrogen sulfide gas is “stripped” through the well treatment microemulsions. Preferably, the inventive microemulsion is periodically injected into problem wells to mitigate hydrogen sulfide production. Alternatively, the microemulsion can be injected downhole via capillary tubing on a continuous basis. In yet another alternate embodiment, the well treatment microemulsion can be placed in a container that is placed in fluid communication with the hydrogen sulfide.


It is clear that the present invention is well adapted to carry out its objectives and attain the ends and advantages mentioned above as well as those inherent therein. While presently preferred embodiments of the invention have been described in varying detail for purposes of disclosure, it will be understood that numerous changes may be made which will readily suggest themselves to those skilled in the art and which are encompassed within the scope of the appended claims and within the spirit of the invention disclosed in the written description.

Claims
  • 1. A well treatment microemulsion having an internal aqueous phase and an external oil phase, the well treatment microemulsion comprising: about 35% to about 45% by weight of an oil in the external phase;about 21% to about 40% by weight of an emulsifying surfactant having a hydrophile lipophile balance of between 10 and 18, wherein the surfactant comprises a surfactant selected from the group consisting of ethoxylated castor oil comprising 25-45 moles of ethylene oxide, ethoxylated alcohols comprising 5-20 moles of ethylene oxide, ethoxylated amides comprising 5-20 moles of ethylene oxide, and ethoxylated fatty acids comprising 5-20 moles of ethylene oxide;about 1% to about 35% by weight of an alcohol;and the internal aqueous phase comprises about 9% to about 16% by weight water.
  • 2. The well treatment microemulsion of claim 1, wherein the oil external phase comprises a hydrocarbon terpene.
  • 3. The well treatment microemulsion of claim 2, wherein the oil external phase comprises at least one terpene hydrocarbon derived from the group of terpene hydrocarbon sources consisting of citrus, pine, eucalyptus, and peppermint.
  • 4. The well treatment microemulsion of claim 1, wherein the oil external phase comprises d-limonene.
  • 5. The well treatment microemulsion of claim 1, wherein the oil external phase comprises at least one component selected from the group consisting of xylenes, parrafin oil, a mixture of cycloparafinic and isoparaffinic oil, and mineral oil.
  • 6. The well treatment microemulsion of claim 1, wherein the surfactant is selected from the group consisting of ethoxylated alcohols comprising 5-20 moles of ethylene oxide and mixtures of ethoxylated alcohols comprising 5-20 moles of ethylene oxide.
  • 7. The well treatment microemulsion of claim 1, wherein the surfactant comprises a mixture of polyoxyethylene hydrogenated castor oil and sorbitan monooleate having an average hydrophile lipophile balance of about 10.
  • 8. The well treatment microemulsion of claim 7, wherein the oil phase comprises between about 35% and 42% by weight d-Limonene, the surfactant comprises between about 30% and 35% by weight a mixture of polyoxyethylene hydrogenated castor oil and sorbitan monooleate and the aqueous phase comprises between about 10% and 15% by weight water.
  • 9. The well treatment microemulsion of claim 1, wherein the aqueous phase comprises isopropanol.
  • 10. The well treatment microemulsion of claim 1, wherein the surfactant is selected from the group consisting of polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan tristearate and polyoxyethylene sorbitan monolaurate.
  • 11. The well treatment microemulsion of claim 10, wherein the oil phase comprises between about 30% and 45% by weight d-limonene, the surfactant comprises between about 30% and 45% by weight sorbitan monostearate and the aqueous phase comprises between about 10% and 15% by weight water.
  • 12. The well treatment microemulsion of claim 11 further comprising isopropanol.
  • 13. The well treatment microemulsion of claim 1, wherein the oil comprises about 41% to 42% by weight d-limonene, the emulsifying surfactant comprises about 32% to about 33% by weight of polyoxyethylene sorbitan monooleate, the alcohol comprises about 10% to about 12% by weight isopropanol, and the internal aqueous phase comprises about 14% to about 15% by weight water.
  • 14. The well treatment microemulsion of claim 1, wherein the oil comprises about 35% to 36% by weight d-limonene, the emulsifying surfactant comprises about 20% to about 21% by weight of polyoxyethylene sorbitan monooleate, the alcohol comprises about 33% to about 35% by weight isopropanol, and the internal aqueous phase comprises about 10% by weight water.
  • 15. The well treatment microemulsion of claim 1, wherein the oil comprises about 41% to 42% by weight hydrocarbon terpenes, the emulsifying surfactant comprises about 32% to about 33% by weight of polyoxyethylene sorbitan monooleate, the alcohol comprises 10% to about 12% by weight isopropanol, and the internal aqueous phase comprises about 14% to about 15% by weight water.
  • 16. The well treatment microemulsion of claim 1, wherein the oil comprises about 35% to 36% by weight d-limonene, the emulsifying surfactant comprises about 20% to about 21% by weight of polyoxyethylene sorbitan tristearate, the alcohol comprises 33% to about 35% by weight isopropanol, and the internal aqueous phase comprises about 9% to about 10% by weight water.
  • 17. The well treatment microemulsion of claim 1, wherein the oil comprises about 41% to 42% by weight d-limonene, the emulsifying surfactant comprises about 32% to about 33% by weight of polyoxyethylene sorbitan monooleate, the alcohol comprises about 10% to about 12% by weight isopropanol, and the internal aqueous phase comprises about 14% to about 15% by weight water.
  • 18. The well treatment microemulsion of claim 1, wherein the surfactant comprises a surfactant selected from the group consisting of ethoxylated castor oil comprising 25-45 moles of ethylene oxide, ethoxylated amides comprising 5-20 moles of ethylene oxide, and ethoxylated fatty acids comprising 5-20 moles of ethylene oxide.
RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/114,125, filed Nov. 13, 2008, entitled “Water-in-Oil Microemulsions for Oilfield Applications,” the disclosure of which is herein incorporated by reference.

US Referenced Citations (223)
Number Name Date Kind
3060210 De Groote Apr 1961 A
3047062 Meadors Jul 1962 A
3347789 Dickson et al. Oct 1967 A
3368624 Heuer et al. Feb 1968 A
3483923 Darley Dec 1969 A
3710865 Kiel Jan 1973 A
3756319 Holm et al. Sep 1973 A
3760881 Kiel Sep 1973 A
3850248 Carney Nov 1974 A
3919411 Glass et al. Nov 1975 A
4206809 Jones Jun 1980 A
4276935 Hessert et al. Jul 1981 A
4360061 Canter et al. Nov 1982 A
4414128 Goffinet Nov 1983 A
4511488 Matta Apr 1985 A
4650000 Andreasson et al. Mar 1987 A
5008026 Gardner et al. Apr 1991 A
5034140 Gardner et al. Jul 1991 A
5076954 Loth et al. Dec 1991 A
5083613 Gregoli et al. Jan 1992 A
5095989 Prukop Mar 1992 A
5217531 Cheung Jun 1993 A
5247995 Tjon-Joe-Pin et al. Sep 1993 A
5310002 Blauch et al. May 1994 A
5356482 Mehta et al. Oct 1994 A
5587354 Duncan, Jr. Dec 1996 A
5587357 Rhinesmith Dec 1996 A
5652200 Davies et al. Jul 1997 A
5665689 Durbut Sep 1997 A
5676763 Salisbury et al. Oct 1997 A
5697458 Carney Dec 1997 A
5707940 Bush et al. Jan 1998 A
5762138 Ford et al. Jun 1998 A
5784386 Norris Jul 1998 A
5811383 Klier et al. Sep 1998 A
5830831 Chan et al. Nov 1998 A
5874386 Chan et al. Feb 1999 A
5925233 Miller et al. Jul 1999 A
5975206 Woo et al. Nov 1999 A
5977032 Chan Nov 1999 A
5990072 Gross et al. Nov 1999 A
5996692 Chan et al. Dec 1999 A
6046140 Woo et al. Apr 2000 A
6090754 Chan et al. Jul 2000 A
6110885 Chan Aug 2000 A
6112814 Chan et al. Sep 2000 A
6165946 Mueller et al. Dec 2000 A
6173776 Furman et al. Jan 2001 B1
6191090 Mondin et al. Feb 2001 B1
6228830 Vlasblom May 2001 B1
6260621 Furman et al. Jul 2001 B1
6302209 Thompson, Sr. et al. Oct 2001 B1
6364020 Crawshaw et al. Apr 2002 B1
6486115 Weaver et al. Nov 2002 B1
6581687 Collins et al. Jun 2003 B2
6593279 Von Krosigk et al. Jul 2003 B2
6613720 Feraud et al. Sep 2003 B1
6729402 Chang et al. May 2004 B2
6770603 Sawdon et al. Aug 2004 B1
6793025 Patel et al. Sep 2004 B2
6800593 Dobson, Jr. et al. Oct 2004 B2
6818595 Benton et al. Nov 2004 B2
6911417 Chan et al. Jun 2005 B2
6939832 Collins Sep 2005 B2
6984610 VonKrosigk et al. Jan 2006 B2
7021378 Prukop Apr 2006 B2
7134496 Jones et al. Nov 2006 B2
7205262 Schwartz et al. Apr 2007 B2
7205264 Boles Apr 2007 B2
7231976 Berry et al. Jun 2007 B2
7380606 Pursley et al. Jun 2008 B2
7392844 Berry et al. Jul 2008 B2
7407915 Jones et al. Aug 2008 B2
7468402 Yang et al. Dec 2008 B2
7481273 Javora et al. Jan 2009 B2
7514390 Chan Apr 2009 B2
7514391 Chan Apr 2009 B2
7533723 Hughes et al. May 2009 B2
7543644 Huang et al. Jun 2009 B2
7543646 Huang et al. Jun 2009 B2
7544639 Pursley et al. Jun 2009 B2
7547665 Welton et al. Jun 2009 B2
7552771 Eoff et al. Jun 2009 B2
7559369 Roddy et al. Jul 2009 B2
7581594 Tang Sep 2009 B2
7615516 Yang et al. Nov 2009 B2
7621334 Welton et al. Nov 2009 B2
7622436 Tuzi et al. Nov 2009 B2
7655603 Crews Feb 2010 B2
7677311 Abad et al. Mar 2010 B2
7687439 Jones et al. Mar 2010 B2
7709421 Jones et al. May 2010 B2
7712534 Bryant et al. May 2010 B2
7727936 Pauls et al. Jun 2010 B2
7727937 Pauls et al. Jun 2010 B2
7730958 Smith Jun 2010 B2
7825073 Welton et al. Nov 2010 B2
7833943 Van Zanten et al. Nov 2010 B2
7838467 Jones et al. Nov 2010 B2
7846877 Robb Dec 2010 B1
7851414 Yang et al. Dec 2010 B2
7855168 Fuller et al. Dec 2010 B2
7857051 Abad et al. Dec 2010 B2
7886824 Kakadjian et al. Feb 2011 B2
7893010 Ali et al. Feb 2011 B2
7902123 Harrison et al. Mar 2011 B2
7906464 Davidson Mar 2011 B2
7910524 Welton et al. Mar 2011 B2
7931088 Stegemoeller et al. Apr 2011 B2
7960314 Van Zanten et al. Jun 2011 B2
7960315 Welton et al. Jun 2011 B2
7963720 Hoag et al. Jun 2011 B2
7971659 Gatlin et al. Jul 2011 B2
7976241 Hoag et al. Jul 2011 B2
7989404 Kakadjian et al. Aug 2011 B2
7992656 Dusterhoft et al. Aug 2011 B2
7998911 Berger et al. Aug 2011 B1
8043996 Harris Oct 2011 B2
8053396 Huff et al. Nov 2011 B2
8053397 Huang et al. Nov 2011 B2
8057682 Hoag et al. Nov 2011 B2
8091644 Clark et al. Jan 2012 B2
8091645 Quintero et al. Jan 2012 B2
8091646 Quintero et al. Jan 2012 B2
8100190 Weaver et al. Jan 2012 B2
8148303 Van Zanten et al. Apr 2012 B2
8183182 Oliveira et al. May 2012 B2
8206062 Hoag et al. Jun 2012 B2
8207096 van Zanten et al. Jun 2012 B2
8210263 Quintero et al. Jul 2012 B2
8220546 Kakadjian et al. Jul 2012 B2
8227382 Dakin et al. Jul 2012 B2
8231947 Vaidya et al. Jul 2012 B2
8235120 Quintero et al. Aug 2012 B2
8242059 Sawdon Aug 2012 B2
8293687 Giffin Oct 2012 B2
8342241 Hartshorne et al. Jan 2013 B2
8349771 Seth et al. Jan 2013 B2
8356667 Quintero et al. Jan 2013 B2
8357639 Quintero et al. Jan 2013 B2
8372789 Harris et al. Feb 2013 B2
8383560 Pich et al. Feb 2013 B2
8403051 Huang et al. Mar 2013 B2
8404623 Robb et al. Mar 2013 B2
8413721 Welton et al. Apr 2013 B2
8415279 Quintero et al. Apr 2013 B2
8431620 Del Gaudio et al. Apr 2013 B2
8453741 van Zanten Jun 2013 B2
8499832 Crews et al. Aug 2013 B2
8517100 Ali et al. Aug 2013 B2
8517104 Kieffer Aug 2013 B2
8524643 Huff et al. Sep 2013 B2
8551926 Huang et al. Oct 2013 B2
8592350 van Zanten et al. Nov 2013 B2
8684079 Wattenbarger et al. Apr 2014 B2
8778850 Andrecola Jul 2014 B2
8865632 Parnell et al. Oct 2014 B1
20010007663 Von Corswant Jul 2001 A1
20030022944 Gumkowski et al. Jan 2003 A1
20030069143 Collins Apr 2003 A1
20030166472 Pursley et al. Sep 2003 A1
20060014648 Milson et al. Jan 2006 A1
20070123445 Tuzi et al. May 2007 A1
20070293404 Hutchins et al. Dec 2007 A1
20070295368 Harrison et al. Dec 2007 A1
20080274918 Quintero et al. Nov 2008 A1
20080287324 Pursley et al. Nov 2008 A1
20090078415 Fan et al. Mar 2009 A1
20090137432 Sullivan et al. May 2009 A1
20090159288 Horvath Szabo et al. Jun 2009 A1
20090260819 Kurian et al. Oct 2009 A1
20090275488 Zamora et al. Nov 2009 A1
20100022421 Gutierrez et al. Jan 2010 A1
20100173805 Pomerleau Jul 2010 A1
20100216670 Del Gaudio et al. Aug 2010 A1
20100243248 Golomb et al. Sep 2010 A1
20100252267 Harris et al. Oct 2010 A1
20100307757 Blow et al. Dec 2010 A1
20110021386 Ali et al. Jan 2011 A1
20110136706 Carroll et al. Jun 2011 A1
20110146983 Sawdon Jun 2011 A1
20110220353 Bittner et al. Sep 2011 A1
20110237467 Cornette et al. Sep 2011 A1
20110253365 Crews et al. Oct 2011 A1
20110290491 Gupta et al. Dec 2011 A1
20120015852 Quintero et al. Jan 2012 A1
20120035085 Parnell et al. Feb 2012 A1
20120080232 Muller et al. Apr 2012 A1
20120129738 Gupta et al. May 2012 A1
20120149626 Fluck et al. Jun 2012 A1
20120168165 Holcomb et al. Jul 2012 A1
20120181019 Saini et al. Jul 2012 A1
20120193095 Varadaraj et al. Aug 2012 A1
20120208726 Smith et al. Aug 2012 A1
20120234548 Dyer Sep 2012 A1
20120241155 Ali et al. Sep 2012 A1
20120241220 Quintero et al. Sep 2012 A1
20120255887 Holms et al. Oct 2012 A1
20120261120 Del Gaudio et al. Oct 2012 A1
20120285690 Weaver et al. Nov 2012 A1
20120285694 Morvan et al. Nov 2012 A1
20120318515 Cawiezel et al. Dec 2012 A1
20120322697 Zhang Dec 2012 A1
20120325492 Fefer et al. Dec 2012 A1
20130029883 Dismuke et al. Jan 2013 A1
20130048281 Van Zanten et al. Feb 2013 A1
20130079255 Del Gaudio et al. Mar 2013 A1
20130109597 Sarkar et al. May 2013 A1
20130133886 Quintero May 2013 A1
20130137611 Pierce et al. May 2013 A1
20130146288 Smith et al. Jun 2013 A1
20130146545 Pabalan et al. Jun 2013 A1
20130153232 Bobier et al. Jun 2013 A1
20130153234 Bobier et al. Jun 2013 A1
20130192826 Kurian et al. Aug 2013 A1
20130233559 van Zanten et al. Sep 2013 A1
20130244913 Maberry et al. Sep 2013 A1
20130261033 Nguyen Oct 2013 A1
20130292121 Penny et al. Nov 2013 A1
20140110344 Hoag et al. Apr 2014 A1
20140202700 Blair Jul 2014 A1
20140299325 Zelenev et al. Oct 2014 A1
20140332212 Ayers et al. Nov 2014 A1
Foreign Referenced Citations (14)
Number Date Country
2345305 Apr 2000 CA
2394858 Jun 2001 CA
102127414 Jul 2011 CN
102277143 Dec 2011 CN
103614128 Mar 2014 CN
103642477 Mar 2014 CN
1 051 237 Nov 2003 EP
1 378 554 Jan 2004 EP
1 786 879 Feb 2012 EP
2 195 400 Aug 2012 EP
1 880 081 Mar 2013 EP
WO 9949182 Sep 1999 WO
WO 2007011475 Jan 2007 WO
WO 2012158645 Nov 2012 WO
Non-Patent Literature Citations (12)
Entry
[No Author Listed], The HLB system: a time-saving guide to emulsifier selection. ICI Americas Inc. 1976. Revised 1980. 22 pages.
Haw, The HLB system: a time saving guide to surfactant selection. Presentation to the Midwest chapter of the society of cosmetic chemists. Mar. 9, 2004. 39 slides.
ADM, Evolution Chemicals E5789-117 Description. Jun. 2014.
Brost et al., Surfactants assist water-in-oil monitoring by fluroescence. World Oil. Oct. 2008;229(10). Published Online.
Champagne et al., Critical assessment of microemulsion technology for enhancing fluid recovery from tight gas formations and propped fractures. SPE European Formation Damage Conference. Noordwijk, The Netherlands. Jun. 7-10, 2011. SPE-144095. 10 pages.
Crafton et al., Micro-emulsion effectiveness for twenty four wells, eastern green river, wyoming. 2009 SPE Rocky Mountain Petroleum Technology Conference. Denver, Colorado, USA, Apr. 14-16, 2009. SPE-123280. 13 pages.
Howard et al., Comparison of flowback aids: understanding their capillary pressure and wetting properties. SPE Production & Operations. Aug. 2010;:376-87.
Kunieda et al. Evaluation of hydrophile-lipophile balance (HLB) of nonionic surfactants. J Colloid and Interface Sci. Sep. 1985;107(1):107-21.
Yang et al., Optimizing nanoemulsions as fluid flowback additives in enhancing tight gas production. J Petroleum Sci Eng. 2014;121:122-5.
Zelenev et al., Microemulsion technology for improved fluid recovery and enhanced core permeability to gas. 2009 SPE European Formation Damage Conference. Scheveningen, The Netherlands. May 27-29, 2009. SPE 122109. 13 pages.
Zelenev et al., Microemulsion-assisted fluid recovery and improved permeability to gas in shale formations. 2010 SPE International Symposium and Exhibition on Formation Damage Control. Lafayette, Louisiana, USA. Feb. 10-12, 2010. SPE 127922. 7 pages.
Zelenev, Surface energy of north American shales and its role in interaction of shale with surfactants and microemulsions. SPE International Symposium on Oilfield Chemistry. The Woodlands, Texas, USA. Apr. 11-13, 2011. SPE-141459. 7 pages.
Provisional Applications (1)
Number Date Country
61114125 Nov 2008 US